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Cell cycle regulationDiamond–Blackfan anemia (DBA) is a severe congenital anemia characterized by a speciﬁc decrease of
erythroid precursors. The disease is also associated with growth retardation, congenital malformations, a
predisposition for malignant disease and heterozygous mutations in either of the ribosomal protein (RP)
genes RPS7, RPS17, RPS19, RPS24, RPL5, RPL11 and RPL35a. We show herein that primary ﬁbroblasts from
DBA patients with truncating mutations in RPS19 or in RPS24 have a marked reduction in proliferative
capacity. Mutant ﬁbroblasts are associated with extended cell cycles and normal levels of p53 when
compared to w.t. cells. RPS19mutant ﬁbroblasts accumulate in the G1 phase, whereas the RPS24mutant cells
show an altered progression in the S phase resulting in reduced levels in the G2/M phase. RPS19 deﬁcient
cells exhibit reduced levels of Cyclin-E, CDK2 and retinoblastoma (Rb) protein supporting a cell cycle arrest
in the G1 phase. In contrast, RPS24 deﬁcient cells show increased levels of the cell cycle inhibitor p21 and a
seemingly opposing increase in Cyclin-E, CDK4 and CDK6. In combination, our results show that RPS19 and
RPS24 insufﬁcient ﬁbroblasts have an impaired growth caused by distinct blockages in the cell cycle. We
suggest this proliferative constraint to be an important contributing mechanism for the complex extra-
hematological features observed in DBA.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Diamond–Blackfan anemia (DBA) is a rare bone marrow failure
syndrome characterized by absent or decreased number of erythroid
precursors whereas other lineages remain unaffected [1]. At least 50%
of patients display variable developmental defects [2–5] and/or short
stature [6]. The disease is also associated with an increased risk of
developing malignancies [7–9]. Approximately 35% of patients with
DBA are heterozygous for mutations in one of the ribosomal pro-
tein (RP) genes RPS7, RPS17, RPS19, RPS24, RPL5, RPL11 and RPL35a
which suggest that impaired ribosomal function causes the disease
[5,10–12]. The mutations result in perturbed rRNA processing and an
impaired ribosomal subunit formation [13,14]. Still, the mechanisms
whereby disruption of ribosome biogenesis results in anemia, marrow
failure, congenital malformations, short stature and malignant
transformation remain to be deﬁned. Several explanations have
been suggested including downstream effects on protein translation
[15] or impaired extra-ribosomal functions related to individualent of Genetics and Pathology,
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ll rights reserved.ribosomal proteins [16–18]. Another possibility is a direct effect in-
duced by impaired ribosome biogenesis on the cellular stress response
or through cellular toxicity [19,20].
It has been widely accepted that DBA results from a cellular defect
which makes erythroid precursor cells sensitive to apoptosis [19,21].
Hematopoietic cells expressing RPS19 siRNA show an increase in
apoptosis [22], reduced proliferation [23] and cell cycle arrest [24]. A
proliferative defect in hematopoietic progenitors is also supported
from studies of primary CD34+ CD38− cells in patients with RPS19
mutations [23].
We hypothesized that the phenotypic complexity seen in DBA
patients is associated with a cellular growth defect in non-hemato-
poietic tissues. We addressed the questions by the investigation of
primary ﬁbroblasts from two DBA patients with truncating and
heterozygous mutations in RPS19 and RPS24, respectively. We report
here a marked reduction in proliferative capacity of RPS19 and RPS24
mutant ﬁbroblasts when compared to control ﬁbroblasts. The reduced
growth is mainly attributed to a prolonged cell cycle with distinct cell
cycle proﬁles for RPS19 and RPS24 mutations, respectively. The cell
cycle arrest in RPS19 mutant is associated with reduced Cyclin-E/
CDK2 levels, hypophosphorylation of Rb and a G1 arrest. The RPS24
mutant cells show increased p21 levels and increased levels of Cyclin-
E, CDK4 and CDK6. These results have implications for our under-
standing of the mechanisms mediated by ribosomal protein insufﬁ-
ciency in DBA.
Fig. 1. Levels of RPS19 and RPS24 proteins in primary ﬁbroblasts as determined by
western blot. Relative levels of RPS19 protein (white bar) and RPS24 protein (grey bar)
in RPS19 (mut-RPS19) and RPS24 (mut-RPS24) mutant cells as compared to controls
(100% expression). Asterisk (⁎) indicates signiﬁcant differences when compared to
control cells (p<0.05).
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2.1. Patients, mutant cell lines, culture conditions
Primary ﬁbroblasts were obtained by skin punch biopsies from
two DBA patients with a RPS19 acceptor splice site mutation (c.72–
2A>C) and a RPS24 start codon mutation (c.1A>G), respectively, and
healthy control individuals. The patient with an RPS19 mutation is a
5 years old girl treated with corticosteroids and she has a left sided
thumb malformation (loss of thenar muscles) and reduced growth
(−3SD). The patient with RPS24mutation is a 26 years old transfusion
dependent female. She has a short stature (−4SD) and a dysmorphic
facial appearance. Only two ﬁbroblast cell lines were available from
DBA patients with deﬁned mutations. Cells were cultured in 50%
Ham's F-10 (GIBCO) plus 50% RPMI 1640 (GIBCO) supplemented
with 10% fetal bovine serum (GIBCO), 20 IU/ml PEST (GIBCO),
2 mML-glutamine (GIBCO) and 3%Ultroser G (PALL Life Sciences). This
study and the use of human samples were approved by the regional
ethical committee of Uppsala and after informed consent from the
patients and/or their parents.2.2. RNA isolation and northern blotting
Fibroblasts were harvested before they reached 70% conﬂuence.
RNA was isolated using Trizol® (Invitrogen) and rRNA analysis was
performed by northern blot as described [14].2.3. Western blotting
Lysates from primary ﬁbroblasts were separated on a 12% Bis–Tris
SDS-PAGE, transferred to PVDF Immobilon-FL membranes (Millipore)
and hybridized using primary antibodies against RPS19, RPS24
(Swedish Human Proteome Resource project), p53, p-Rb (Cell
Signaling), Rb, CDK2, CDK4, CDK6, Cyclin-D1, Cyclin-E, p21 and p27
(Santa Cruz). Antibodies detecting β-actin (Abcam) were used as
internal controls.2.4. Cell cycle analysis and apoptosis assay
Primary ﬁbroblasts were harvested by trypsinization and ﬁxed in
70% ethanol, incubated with RNase solution and stained with
propidium iodide (PI). 20,000 cells were subjected to ﬂow cytometry
analysis using FACS ﬂow (BD Bioscience) and BD FACSDiva. The
software Modﬁt LT was used for cell cycle analysis. For apoptosis, the
primary ﬁbroblasts were harvested after 24h and 48h of exponential
growth and stained using the TACS Annexin V-FITC assay kit (R&D
systems) prior to ﬂow cytometry using FACS ﬂow (BD Bioscience).
The data were analyzed with BD FACSDiva program.Fig. 2. Growth curves of primary ﬁbroblasts carrying RPS19 and RPS24 mutations,
respectively, and three control ﬁbroblasts. (A) 6800 cells/cm2 were seeded in
duplicates and counted after 48 h and 72 h to measure the generation time (tgen). A
growth curve assuming exponential growth is simulated using equation N=Noeµt
showing the number of cells as a function of time. µ=0.693/tgen. (B) Replotted growth
curves from (A) implementing an apoptosis correction factor (ka) to obtain the adjusted
growth curve equation N=Noekaµt. RPS19 mutant cells (open squares), RPS24 mutant
cells (open circles) and control ﬁbroblasts (open triangles).2.5. Calculation of cell growth, proliferation and generation time
We seeded 6800 ﬁbroblasts/cm2 in duplicates. Cells were counted
after 48h and 72h. Generation times (tgen) for the distinct cell lines
were calculated as follows: tgen = t1t0log2 N1  log2 N2 (Eq. (1)). Where
tn=time (hours) and Nn=number of cells at time point n. The
growth rates were estimated assuming exponential growth by
incorporating the calculated generation time into an exponential
growth equation N=Noeµt (Eq. (2)), describing the increase in cell
numbers over time (t), as deﬁned by their respective growth rate (µ).
Growth rate is deﬁned as µ=0.693/tgen. N=number of cells at time
t;No=initial number of cells at time to. Proliferationwas re-estimated
by introducing a distinct apoptosis rate correction factor (ka) into
Eq. (2) to obtain an adjusted growth curve: N=Noekaµt (Eq. (3)).3. Results and discussion
3.1. Downregulation of RPS19 and RPS24 in primary ﬁbroblast cells from
DBA patients
Themolecularmechanismmediated by ribosomal protein deﬁciency
in DBA is poorly understood [19]. The predominant clinical feature is
restricted to the erythroid lineage but up to 50% of patients with DBA
showdevelopmental abnormalities and short stature (>−2SD). Similar
to other bone marrow failure syndromes a predisposition for acute
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have critical functions in all cells and the relative tissue speciﬁcity
observed in DBA has led to the suggestion of extra-ribosomal functions
for the mutant proteins in erythropoiesis [17,18]. Yet another
explanation, based on the recent identiﬁcation of perturbed ribosome
biogenesis in ribosomal protein-deﬁcient hematopoietic cells, may be
that erythroblasts, because of a high proliferation rate, are particularly
sensitive to defects in ribosome biogenesis [25]. This may increase their
sensitivity to cellular stress and an impaired response to proliferation
and differentiation. In order to clarify the possible effect of ribosomal
protein gene mutations in non-hematopoietic tissues we analyzed
primary ﬁbroblasts fromDBA patients with truncating RPS19 and RPS24
mutations, respectively. Western blot analysis on ﬁbroblasts derived
from the two DBA patients and three healthy controls were performed
using polyclonal rabbit antisera against RPS19 and RPS24, respectively.
The level of RPS19 in RPS19mutated ﬁbroblasts was reduced to 50% of
that in controls, whereas RPS19was decreased to 83% in RPS24mutated
ﬁbroblasts (Fig. 1). The level of RPS24 protein in both RPS24 mutated
and RPS19 mutated DBA ﬁbroblasts is decreased to 70% of that in
controls. This suggests that both mutations result in haploinsufﬁciency.Fig. 3. Cell cycle analysis of human primary ﬁbroblasts. The cell cycle phases were measured
the RPS19mutated (mut-RPS19), RPS24mutated (mut-RPS24) cells and three controls. The
cells in distinct cell cycle phases from two independent experiments. The average percentag
deviations. Asterisk (⁎) indicates signiﬁcant differences when compared to control cells inThe observed concomitant reduction of both small subunit proteins in
mutant cell lines may be explained by a deﬁcient assembly of the small
subunit when one component is present in insufﬁcient amounts. A
similar coordinated down regulation of ribosomal proteins from the
same subunit was recently reported in HeLa cells subjected to siRNA
knock-down of speciﬁc RPs [26] and in patient derived cell lines [27].
3.2. Reduced proliferation and extended cell cycles in RPS19 and RPS24
mutant ﬁbroblasts
Increased apoptosis of erythroid precursors has been considered a
major cause of anemia in DBA [19]. However, more recent data have
also suggested proliferation defects and a speciﬁc cell cycle arrest in
hematopoietic cells as contributing mechanisms in the disease
[22,24]. We performed a growth assay to clarify any defect in RPS19
and RPS24 mutant ﬁbroblasts from the two DBA patients by
comparing them to passage matched ﬁbroblasts from two healthy
individuals. Cells were seeded at a density of 6800 cells/cm2 and
counted after 48h and 72h of exponential growth to deduce the
generation time. The ﬁbroblasts with RPS19 and RPS24 mutationsby propidium iodide labeling. (A) Representative histograms from cell cycle analysis of
cell cycle phases G1, S and G2/M are indicated. (B) Diagram showing the distribution of
es of cells in the different cell cycle phases (G1, S and G2/M) are shown with standard
the same phase, respectively (p<0.05).
Fig. 4. Analysis of p53, p21 and p27 protein levels in ﬁbroblasts carrying RPS19
mutation (mut-RPS19), RPS24 mutation (mut-RPS24) and controls (100% expression).
Western blot analyses were normalized to β-actin. (A) p53 protein expression. The
diagram illustrates the average of two independent measurements and standard
deviations without signiﬁcant differences. Representative analysis (bottom) using
antibodies against p53 and β-actin, respectively. (B) Relative levels of p21 in RPS19 and
RPS24 mutant cells from two different experiments and controls (100% expression).
Asterisk (⁎) denotes signiﬁcant differences compared to controls (p<0.05). Represen-
tative analysis (bottom) using antibodies against p21 and β-actin, respectively.
(C) Relative levels of p27 in RPS19 and RPS24 mutant cells as compared to controls
(100% expression). Representative analysis (bottom) using antibodies against p27 and
β-actin, respectively.
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generation time of 37h and 41h, respectively, as opposed to 25 h in
the control ﬁbroblasts (p<0.05; Fig. 2A). We used the estimated
generation time to simulate growth curves for the mutant cell lines
and controls, assuming exponential growth (for details see Materials
and methods). The simulated curves illustrate a difference in growth
capacity of the mutant cells compared to the control ﬁbroblasts
(Fig. 2A).
In order to clarify the causes of reduced growth in RPS19 and
RPS24 mutant cells, we analyzed the degree of apoptosis at 24h and
48h, respectively. The average apoptotic fractions of ﬁbroblasts
revealed by Annexin V staining in RPS19 and RPS24 mutant cells
were 14.15% and 11.45%, respectively. The apoptosis in RPS19 and
RPS24 mutant ﬁbroblasts are signiﬁcantly increased (p<0.05) when
compared to the average apoptotic fraction in control cells (5.95%;
Supplementary Fig. S1). This difference is similar to what has been
shown after siRNA knock-down of RPS19 in TF-1 cells [22]. We then
integrated the apoptosis rate for the mutant and control cells into the
exponential growth equations by introducing an apoptosis constant
(ka) and we recalculated the proliferation curves (Fig. 2B). We
assumed that the simulated curves for control andmutant cells would
coincide if the increased apoptosis alone causes the reduced
proliferative capacity in mutant cells. Interestingly, we observed a
marked difference in the curve slopes between DBA derived
ﬁbroblasts and control cells. The corrected generation time was
estimated to 32h for RPS19 mutant cells and 37h for RPS24 mutant
cells when integrating apoptosis (Fig. 2B). The corresponding
generation time for control cells was 24h. The prolonged generation
time in the RPS19 and RPS24 mutant cells is signiﬁcant (p<0.05)
when compared to control cells. The results indicate that the reduced
growth in DBA derived ﬁbroblasts is mainly attributed to reduced
proliferative capacity whereas the contribution from increased
apoptosis is less signiﬁcant.
3.3. Different cell cycle distribution of RPS19 and RPS24 mutant
ﬁbroblasts
The prolonged cell cycles in mutant ﬁbroblasts prompted us
to investigate the proportion of cells in different phases (G1, S and
G2/M) using propidium iodide (PI) staining (Fig. 3). The RPS19
mutant cells showed a signiﬁcantly larger proportion of cells in
the G1 phase (p=0.036) and a reduced number in the S phase
(p=0.025) when compared to control cells (Figs. 3A and B). The
RPS24 mutant ﬁbroblasts showed a distinct proﬁle with a signiﬁcant
decrease in the number of cells in the G2/M phase (p=0.042).
Furthermore, the number of RPS24 mutant cells decreased gradually
throughout the S-phase (Fig. 3A). The results indicate that the RPS19
mutation results in an arrest of cells in the G1 phase whereas the
RPS24 mutation leads to a perturbed S phase progression, possibly
due to a defect already at the G1 to S transition.
3.4. Impaired rRNA maturation in RPS19 and RPS24 mutant cells
Ribosomal proteins are pivotal for the maturation and assembly of
ribosomal subunits. Previous reports have shown that RPS19 muta-
tions cause impaired 18S rRNA synthesis leading to reduced 40S
assembly [13,14]. We analyzed rRNA intermediates (45S, 41S, 30S,
21S, 18SE) in the mutant ﬁbroblast cell lines and control cells by
northern blot analysis using β and γ probes complementary to 18S
rRNA [14]. Analysis of RPS19 mutant cells showed a signiﬁcant
increase in the relative levels of 21S and 41S rRNA with increased
21S/18SE (p=0.029) and 41S/30S (p=0.040) ratios when compared
to controls. The RPS24mutant cells showed increased relative levels of
30S rRNA resulting in a reduced 41S/30S ratio (p=0.047) as well as
reduced amounts of 21S and 18SE pre-rRNA leading to an increased
30S/21S ratio (p=0.029) when compared to the control cells
Fig. 5.Western blot analysis of the cell cycle regulators Cyclin-E, CDK4, CDK6, Cyclin-D1, CDK2 and retinoblastoma protein (Rb) in ﬁbroblasts carrying RPS19mutation (mut-RPS19),
RPS24 mutation (mut-RPS24) and three controls (100% expression). Averages of at least two independent experiments are shown with standard deviations. The western analysis
was normalized to β-actin and representative blots are illustrated below each diagram. Asterisk (⁎) denotes signiﬁcant differences (p<0.05) compared to controls. (A) Relative
levels of Cyclin-E. (B) Relative levels of CDK4. (C) Relative levels of CDK6. (D) Relative levels of Cyclin-D showing tendencies for variations in RPS19 and RPS24mutant cells but these
are non-signiﬁcant. (E) Relative levels of CDK2. (F) Relative levels of phosphorylated Rb (p-Rb; white bars) and non-phosphorylated Rb (Rb; grey bar) proteins.
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the extended cell cycles observed in our study as well as previous
studies on cells with RPS19 and RPS24 mutations [14,27,28].
3.5. Dysregulated cell cycle proteins in RPS19 and RPS24 deﬁcient
ﬁbroblasts
The reduced growth and the aberrant cell cycle distribution of the
mutant ﬁbroblasts prompted us to analyze speciﬁc proteins involved
in cell cycle regulation.We selected distinct cell cycle regulators in the
G1 and S phases. We ﬁrst analyzed the protein levels of p53 in RPS19
and RPS24 mutant cells. The levels were within the normal range
when compared to control ﬁbroblasts (Fig. 4A). We then analyzed the
two G1 check-point proteins p21 and p27. The levels of p21 were
found signiﬁcantly increased in RPS24 mutant ﬁbroblasts suggesting
cellular stress in the G1 phase (Fig. 4B). The p21 levels were found
normal in RPS19 mutant cells and the p27 levels were within the
normal range in both RPS19 and RPS24mutant cell lines (Fig. 4C). Two
major targets for p21 in the G1 phase are the Cyclin-D dependent
kinase CDK4 and CDK6 complex in early G1 phase and the Cyclin-E-
CDK2 complex inmid to late G1 phase required for phosphorylation of
the retinoblastoma protein (Rb) and entry into the S phase [29–33]. In
the RPS24 mutant cells, the analysis revealed increased levels of
Cyclin-E, CDK4 and CDK6 whereas the levels of Cyclin-D and CDK2
were normal with a tendency for increased levels (Figs. 5A–E). This
suggests that RPS24 mutant cells progress through the G1 phase and
transit into the S-phase. This is consistent with the observed
distribution of cells within the different cell cycle phases, showing a
normal proportion of cells in G1 phase. The increased p21 level in
RPS24 mutant cells, indicating cellular stress, is also consistent with
a relative S phase blockage and may explain the gradual decrease in
cell numbers during the S phase and the signiﬁcant decrease in
number of cells in G2/M phase observed on cell cycle histograms
(Fig. 3A). In contrast, the RPS19mutant cells showed reduced levels of
Cyclin-E and CDK2 whereas the Cyclin-D, CDK4 and CDK6 appeared
normal (Figs. 5A–E). These results indicate that RPS19 mutant cells
display a G1 block preceding the arrest in RPS24 mutant cells. This is
also supported by the reduced level of phosphorylated Rb restricted to
RPS19 mutant cells indicating impaired progression into the S-phase
(Fig. 5F). Thus, the marked prolongation of the cell cycle in the RPS19
and RPS24 mutant ﬁbroblasts with their abnormal and distinct phase
distributions are consistent with alterations in cell cycle regulators.
The combined results from the analysis of Cyclin-E, Cyclin-D, CDK2/4/
6 and Rb indicate that the RPS19 mutation results in an arrest in the
G1 phase in ﬁbroblasts whereas the RPS24mutation results in a defect
in the S phase. Interestingly, this is associated with normal levels of
p53, a key regulator of p21 and a gate keeper in the G1 progression.
The cell cycle inhibitor p53 has previously been found to accumulate
in Rps19 mutant mouse and zebraﬁsh models [34,35]. This indicates
that mutations in ribosomal protein genes cause cellular stress and
activate cell cycle inhibitors. Activated cell cycle inhibitors may also
explain the reduced growth and, with acquired mutations in e.g. p53,
the tumor predisposition observed in zebraﬁsh and humans with
mutations in ribosomal protein genes [6,20,34–36].
The regulatory mechanism by which impaired ribosome biogen-
esis results in prolonged cell cycle with distinct arrests is yet unclear.
Incomplete ribosome assemblymay directly contribute to this process
through activation of cell cycle regulators and different cellular stress
responses. It has been suggested that perturbed ribosome assembly
destabilises the nucleolus and affects the coresident cell cycle
machinery leading to cell cycle progression defects [37]. Impaired
ribosomal function may also exert downstream effects on protein
translation, which in turn are responsible for the complex DBA
phenotype. Previous reports have shown that reduced levels of
ribosomal proteins trigger apoptosis and cell cycle arrest in a p53
dependent manner [34–36]. Repeated analysis of total p53 levels bywestern blot and mRNA analysis using qRT/PCR (data not shown) in
this study showed no signiﬁcant differences between RPS19 and
RPS24 mutant cells and control ﬁbroblasts (Fig. 4A). This could
possibly be explained by the assumption that ﬁbroblasts are less
sensitive to stress induced by the mutations in ribosomal protein
genes or that mutant cells bypass p53 and directly activate
downstream targets of importance for a cellular stress response
and/or cell cycle regulation. Both these possibilities are compatible
with the results presented herein.
Our combined results indicate that primary ﬁbroblasts with RPS19
and RPS24 gene mutations and perturbed ribosome biogenesis are
associated with a marked proliferative defect, distinct cell cycle
arrests and dysregulated cell cycle proteins. The increased apoptosis
has little effect on the overall cell growth. Our observations are
restricted to two available cell lines but may have implications for
non-hematopoietic features in DBA such as short stature, develop-
mental abnormalities resulting in various malformations and the
predisposition to malignant disease. Haploinsufﬁciency for several
ribosomal proteins in other species such as Drosophila and mice are
associatedwith reduced body size [38]. Further studies are required to
more precisely clarify the mechanisms involved in the cellular growth
reduction and cell cycle control caused by RPS19 and RPS24
mutations.
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